At a glance
ClinicalIndex Comparison RecordN/ACompleted· 80 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacogenomic Analysis of 6-mercaptopurine in Pediatric Acute Lymphoblastic Leukemia
In Brief
An observational study for Acute Lymphoblastic Leukemia, Pediatric and Adverse Drug Event. Completed, enrolled 80 participants across 1 site.
Detailed Summary
This is a retrospective biobank study evaluating the impact of novel genetic variants in a population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsStanford University
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartFeb 2021
First PostedFeb 2021
Primary CompletionAug 2021
Study CompletionNov 2021
TodayJul 2026
First PostedFeb 25, 2021
Enrollment StartFeb 23, 2021
Primary CompletionAug 30, 2021
Study CompletionNov 10, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.4 years ago